MedTrace Logo

PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina

NCT00682565 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2018-08-21

Study results available
· View outcomes & findings →

Summary

This study investigates whether symptom-limited exercise capacity in ischemic cardiomyopathy patients with angina is deleteriously affected by treatment with CK-1827452.

Conditions

Interventions

DRUG

CK-1827452 24mg and 6 mg iv infusion

I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr

DRUG

CK-1827452 12.5mg capsule

12.5mg oral immediate release capsule

DRUG

CK-1827452 48 mg and 11 mg iv infusion

I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr

DRUG

CK-1827452 25mg capsule

25mg oral immediate release capsule

DRUG

Placebo iv infusion

Matching placebo iv infusion

DRUG

Placebo capsule

Matching placebo oral immediate release capsule

Sponsors & Collaborators

  • Cytokinetics

    lead INDUSTRY

Principal Investigators

  • Andrew A Wolff, MD, FACC · Cytokinetics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-11-30
Completion
2009-03-31

Countries

  • Georgia
  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00682565 on ClinicalTrials.gov